LAT1 is a putative therapeutic target in endometrioid endometrial carcinoma

International Journal of Cancer

Volumn 139, Issue 11, 2016, Pages 2529-2539

  Marshall, Amy D ^a,b   van Geldermalsen, Michelle ^a,b   Otte, Nicholas J ^a,b   Anderson, Lyndal A ^b,c   Lum, Trina ^c   Vellozzi, Melissa A ^a,b   Zhang, Blake K ^a,b   Thoeng, Annora ^a,b   Wang, Qian ^a,b   Rasko, John E J ^a,b,c   Holst, Jeff ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

BCH; endometrial carcinoma; endometrioid adenocarcinoma; l type amino acid transporters; LAT1

Indexed keywords

2 AMINOBICYCLO (2,2,1) HEPTANE 2 CARBOXYLIC ACID; AMINO ACID TRANSPORTER; ANTINEOPLASTIC AGENT; L TYPE AMINO ACID TRANSPORTER 1; LEUCINE; PROTEIN INHIBITOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CARCINOMA CELL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; GENE EXPRESSION; HEC1A CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; ISHIKAWA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TUMOR SPHEROID;

EID: 84987936706     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30371     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
2. Kurman RJ, Caracangiu ML, Herrington CS, et al. World Health Organization Classification of Tumours of Female Reproductive Organs, 4th ed.
3. McCarty MF. Mortality from Western cancers rose dramatically among African-Americans during the 20th century: Are dietary animal products to blame? Med Hypotheses 2001;57:169–74.
4. Thomas DB. Epidemiologic studies of cancer in minority groups in the western United States. Natl Cancer Inst Monogr 1979; 103–13.
5. Bravi F, Bertuccio P, Turati F, et al. Nutrient-based dietary patterns and endometrial cancer risk: An Italian case-control study. Cancer Epidemiol 2015;39:66–72.
6. O'Connell TM. The complex role of branched chain amino acids in diabetes and cancer. Metabolites 2013;3:931–45.
7. Kanai Y, Segawa H, Miyamoto K, et al. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998;273:23629–32.
8. Mastroberardino L, Spindler B, Pfeiffer R, et al. Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 1998;395:288–91.
9. Babu E, Kanai Y, Chairoungdua A, et al. Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem 2003;278:43838–45.
10. Bodoy S, Martin L, Zorzano A, et al. Identification of LAT4, a novel amino acid transporter with system L activity. J Biol Chem 2005;280:12002–11.
11. Shennan DB, Thomson J, Gow IF, et al. L-leucine transport in human breast cancer cells (MCF-7 and MDA-MB-231): Kinetics, regulation by estrogen and molecular identity of the transporter. Biochim Biophys Acta 2004;1664:206–16.
12. Shennan DB, Thomson J. Inhibition of system L (LAT1/CD98hc) reduces the growth of cultured human breast cancer cells. Oncol Rep 2008;20:885–9.
13. Wang Q, Bailey CG, Ng C, et al. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res 2011;71:7525–36.
14. Wang Q, Tiffen J, Bailey CG, et al. Targeting amino acid transport in metastatic castration-resistant prostate cancer: Effects on cell cycle, cell growth, and tumor development. J Natl Cancer Inst 2013;105:1463–73.
15. Kaira K, Sunose Y, Arakawa K, et al. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer 2012;107:632–8.
16. Toyoda M, Kaira K, Ohshima Y, et al. Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer. Br J Cancer 2014;110:2506–13.
17. Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 2008;98:742–8.
18. Sherman ME. Theories of endometrial carcinogenesis: A multidisciplinary approach. Mod Pathol 2000;13:295–308.
19. Risinger JI, Allard J, Chandran U, et al. Gene expression analysis of early stage endometrial cancers reveals unique transcripts associated with grade and histology but not depth of invasion. Frontiers Oncol 2013;3:139.
20. Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67–73.
21. Zaino RJ. FIGO staging of endometrial adenocarcinoma: A critical review and proposal. Int J Gynecol Pathol 2009;28:1–9.
22. Eritja N, Llobet D, Domingo M, et al. A novel three-dimensional culture system of polarized epithelial cells to study endometrial carcinogenesis. Am J Pathol 2010;176:2722–31.
23. Tomi M, Mori M, Tachikawa M, et al. L-type amino acid transporter 1-mediated L-leucine transport at the inner blood-retinal barrier. Invest Ophthalmol Vis Sci 2005;46:2522–30.
24. Tiffen JC, Bailey CG, Marshall AD, et al. The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells. Int J Cancer 2013;133:1603–13.
25. Wang Q, Beaumont KA, Otte NJ, et al. Targeting glutamine transport to suppress melanoma cell growth. Int J Cancer 2014;135:1060–71.
26. Garcia-Dios DA, Lambrechts D, Coenegrachts L, et al. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol Oncol 2013;128:327–34.
27. Llaurado M, Ruiz A, Majem B, et al. Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease. Mol Cell Endocrinol358:244–55.
28. Nishida M, Kasahara K, Kaneko M, et al. Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Nihon Sanka Fujinka Gakkai Zasshi 1985;37:1103–11.
29. Way DL, Grosso DS, Davis JR, et al. Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture. In Vitro 1983;19:147–58.
30. Kuramoto H, Hamano M, Imai M, et al. HEC-1 cells: Establishment of an in vitro experimental system in endometrial carcinoma. In: Kuramoto H, Nishida M, eds. Cell and Molecular Biology of Endometrial Carcinoma. Tokyo: Springer-Verlag, 2003;3–34.
31. Richardson GS, Dickersin GR, Atkins L, et al. KLE: A cell line with defective estrogen receptor derived from undifferentiated endometrial cancer. Gynecol Oncol 1984;17:213–30.
32. Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: Have they different risk factors? J Clin Oncol 2013;31:2607–18.
33. Jones ME, van Leeuwen FE, Hoogendoorn WE, et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries. Breast Cancer Res 2012;14:R91.
34. Haidopoulos D, Simou M, Akrivos N, et al. Risk factors in women 40 years of age and younger with endometrial carcinoma. Acta Obstet Gynecol Scand 2010;89:1326–30.
35. Wright JD, Buck AM, Shah M, et al. Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol 2009;27:1214–9.
36. Nakayama K, Nakayama N, Ishikawa M, et al. Endometrial serous carcinoma: Its molecular characteristics and histology-specific treatment strategies. Cancers 2012;4:799–807.
37. Floyd AD. Image analysis in immunohistochemistry. In: Shi S, Taylor CR, eds. Antigen Retrieval Immunohistochemistry Based Research Diagnostics. Hoboken, New Jersey: John Wiley and Sons, 2010.
38. Watanabe J, Yokoyama Y, Futagami M, et al. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression. Int J Gynecol Cancer 2014;24:659–63.
39. Alkushi A, Kobel M, Kalloger SE, et al. High-grade endometrial carcinoma: Serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol 2010;29:343–50.
40. Bartlett JM, Thomas J, Ross DT, et al. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res 2010;12:R47.
41. Wang Q, Holst J. L-type amino acid transport and cancer: Targeting the mTORC1 pathway to inhibit neoplasia. Am J Cancer Res 2015;5:1281–94.
42. Kim MS, Wu KY, Auyeung V, et al. Leucine restriction inhibits chondrocyte proliferation and differentiation through mechanisms both dependent and independent of mTOR signaling. Am J Physiol Endocrinol Metab 2009;296:E1374–82.
43. Han JM, Jeong SJ, Park MC, et al. Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway. Cell 2012;149:410–24.
44. Wang Q, Grkovic T, Font J, et al. Monoterpene glycoside ESK246 from Pittosporum targets LAT3 amino acid transport and prostate cancer cell growth. ACS Chem Biol 2014;9:1369–76.
45. D'Andrilli G, Bovicelli A, Paggi MG, et al. New insights in endometrial carcinogenesis. J Cell Physiol 2012;227:2842–6.
46. Cheung LW, Hennessy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011;1:170–85.
47. Blando J, Portis M, Benavides F, et al. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am J Pathol 2009;174:1869–79.
48. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29–39.
49. Rosilio C, Nebout M, Imbert V, et al. L-type amino-acid transporter 1 (LAT1): A therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia. Leukemia 2015;29:1253–1256.
50. Poncet N, Shi Y-B, Taylor P, et al. LAT1 (Slc7a5) null mice are embryonic lethal and exhibit neural tube defects (896.5). FASEB J 2014;28:896.